NCT03079518 (Iron Turtle) is a Phase 2 clinical trial of Ferric Carboxymaltose in Heart Failure, Systolic, sponsored by RWTH Aachen University.

Who is sponsoring NCT03079518?

NCT03079518 is sponsored by RWTH Aachen University.

What drugs are being tested in NCT03079518?

Interventions in NCT03079518: Ferric Carboxymaltose, blood withdrawal.

What condition does NCT03079518 study?

NCT03079518 studies Heart Failure, Systolic, Iron Deficiency.

Is NCT03079518 still recruiting?

NCT03079518 is currently completed. Last updated 6 December 2017.

Last reviewed 2017-12-06 · How we verify

NCT03079518: Iron Turtle

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency

Completed Phase 2 Last updated 6 December 2017

What this trial tests

Phase 2 trial testing Ferric Carboxymaltose in Heart Failure, Systolic in 23 participants. Completed in 25 October 2017.

Timeline

10 March 2017

Primary endpoint
25 October 2017

25 October 2017

Quick facts

Lead sponsor	RWTH Aachen University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	23
Start date	10 March 2017
Primary completion	25 October 2017
Estimated completion	25 October 2017
Sites	1 location across Germany

Drugs / interventions tested

Ferric Carboxymaltose (FERRIC CARBOXYMALTOSE) — full drug profile →
blood withdrawal — full drug profile →

Conditions studied

Heart Failure, Systolic — all drugs for Heart Failure, Systolic →
Iron Deficiency — all drugs for Iron Deficiency →

Sponsor

RWTH Aachen University

Who can join

18 and older, any sex, with Heart Failure, Systolic or Iron Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Effects of ferric carboxymaltose single HD (1000 mg) infusion upon FGF23 in patients with isolated HFREF compared to patients with HFREF+CKD (all pts with iron deficiency). This study aims at identification of the optimal target population for a follow-up ("main") study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage.
Brandenburg V, Heine GH, Marx N, Stöhr R. · · 2020 · cited 2× · PMID 32215701 · DOI 10.1007/s00392-020-01630-z

Verify or expand the search:

Other trials of Ferric Carboxymaltose

Trials testing the same drug.

NCT07053475 — IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches · Phase 4 · recruiting
NCT03466983 — A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxyma · Phase 4 · completed
NCT02949947 — Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Re · Phase 2 · terminated
NCT03380520 — Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy · Phase 4 · completed
NCT03218384 — Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency · Phase 2 · terminated

Other recruiting trials for Heart Failure, Systolic

Currently open trials in the same condition.

NCT07199088 — Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Ac · NA · recruiting
NCT06336746 — Cardiac Performance During Steep Trendelenburg Position in Patients Undergoing Robotic Surgery Surgery. · recruiting
NCT06675552 — Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany · recruiting
NCT06332391 — Paced Heart Rate Acceleration for Cardiac Conditioning · NA · recruiting
NCT05632432 — Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery · NA · recruiting

Other RWTH Aachen University trials

Trials by the same sponsor.

NCT06390384 — Prevention Programme for Improvement of Well-being and Level of Participation in Adolescents With Enhanced Psychiatric B · NA · not yet recruiting
NCT07322796 — Smoking Cessation Before Bronchoscopy or CT-guided Puncture · recruiting
NCT04996914 — Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma · NA · not yet recruiting
NCT07053956 — Impact of Chewing Gum on FeNO Levels in Patients With Bronchial Asthma · NA · completed
NCT07140536 — The Impact of Treadmills and Cooler Environments for Office Workplaces on Ergonomics, Heating Energy Requirements, Perfo · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03079518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RWTH Aachen University
Last refreshed: 6 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03079518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing